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OBJECTIVES: To profile utilization of olanzapine and
risperidone at baseline in a prospective study of treat-
ment for schizophrenia, and evaluate factors associated
with the receipt of these medications. METHODS: Data
were obtained from the US Schizophrenia Care and As-
sessment Program (US-SCAP), a prospective study of
treatment for schizophrenia in six large community sys-
tems of care. The first 1,231 patients enrolled in the
study were evaluated, including 321 patients treated with
olanzapine and 231 patients treated with risperidone.
RESULTS: 45 percent of patients received olanzapine
and/or risperidone over a six-month baseline interval.
Olanzapine-treated patients received a median dose of
10.4 mg/day [mean 13.0, mode 10]. Risperidone-treated
patients received a median dose of 6.0 mg/day [mean 5.6,
mode 6]. Among patients receiving both medications, ris-
peridone was two times more likely to precede olanza-
pine than the reverse order. Patients initiating treatment
with olanzapine were significantly more likely to receive
prior treatment with clozapine and/or depot antipsychot-
ics (P  0.01) than risperidone-treated patients. Patients
treated with olanzapine only were significantly less likely
to receive antiparkinsonian or anticholinergic agents
(P  0.01) during the treatment interval than patients
treated with risperidone only. CONCLUSIONS: Dosages
of olanzapine and risperidone in this large community
sample of patients receiving usual care were consistent
with expectations from controlled studies. Olanzapine-
treated patients were more likely to receive prior thera-
pies associated with treatment resistance or noncompli-
ance than risperidone-treated patients, suggesting the
possibility of greater severity in the olanzapine treatment
group. Olanzapine-treated patients were less likely to re-
ceive antiparkinsonian or anticholinergic medications
during therapy.
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Schizophrenia affects less than 1% of the US population,
yet its treatment accounts for more than 2.5% of total
healthcare expenditures, making it the most costly illness
to treat in psychiatry. OBJECTIVES: The purpose of this
study is to document the treatment experience of patients
with schizophrenia in a managed care population.
METHODS: This study utilized an administrative claims
database from PacifiCare in California. Prescription and
encounter claims from 1/1/95–9/1/99 in California,
Texas, Oklahoma, Washington and Oregon were evalu-
ated using an intent-to-treat analysis. Only adults were
included, with 6 prior months eligibility, no antipsy-
chotic medication use in the 120 days before treatment
start (washout period), continuous antipsychotic use for
120 days, and 365 days of eligibility following treat-
ment start. RESULTS: Of the 4,388 PacifiCare members
qualifying for this analysis, only 232 (5%) had a diagno-
sis of schizophrenia in the 180 days prior to the treat-
ment start. In 4,321 (98%) of the antipsychotic treatment
episodes, a single antipsychotic agent was initiated. Of
those initiating antipsychotic mono-therapy, 3,286 (76%)
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